TARGETED THERAPY VS
IMMUNOTHERAPY
Two pillars of precision cancer medicine compared โ one blocks molecular pathways driving tumor growth, the other unleashes the immune system.
Two Approaches to Precision Oncology
Both targeted therapy and immunotherapy represent precision medicine, but they work differently. Targeted therapy blocks specific molecular drivers within cancer cells. Immunotherapy activates or engineers the immune system to recognize and destroy tumors.
โTargeted therapy strikes the tumor's Achilles heel; immunotherapy summons the army.โ
Targeted Therapy vs Immunotherapy
Targeted Therapy
- Blocks molecular pathwaysInhibits specific proteins (kinases, receptors) driving tumor growth.
- Requires specific biomarkerHER2+, EGFR+, BRAF V600E, ALK+ etc.
- High initial response rates60-80% in biomarker-selected patients.
- Resistance develops over timeTumors often develop bypass mutations within 1-2 years.
Immunotherapy
- Activates immune systemRemoves checkpoints (PD-1/PD-L1) or engineers immune cells.
- Biomarkers are prognostic, not always requiredPD-L1, TMB, MSI-H guide but don't always determine eligibility.
- Lower but more durable responses20-50% ORR, but responses can last years.
- Immune memory prevents recurrenceTrained immune cells can provide long-term surveillance.
Side-by-Side Comparison
| Factor | Targeted Therapy | Immunotherapy |
|---|---|---|
| Mechanism | Molecular pathway inhibition | Immune activation / checkpoint blockade |
| Biomarker needed | Yes (mandatory) | Helpful but not always required |
| Response rate | 60-80% (biomarker+) | 20-50% (monotherapy) |
| Duration of response | 6-18 months (resistance common) | Often years if responsive |
| Side effects | Rash, diarrhea, liver toxicity | irAEs: colitis, thyroiditis, pneumonitis |
| Oral vs IV | Many oral options | Mostly IV infusions |
| Combination use | Combined with immunotherapy | Combined with chemo or targeted |
When Is Each Approach Preferred?
Targeted Therapy First
EGFR+ NSCLC, HER2+ breast cancer, BRAF V600E melanoma, BCR-ABL+ CML โ where validated molecular targets exist.
Immunotherapy First
PD-L1 high NSCLC, advanced melanoma, MSI-H tumors, renal cell carcinoma โ where immune activation is most effective.
Frequently Asked Questions
Targeted Therapy vs Immunotherapy
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Need Help Deciding Between Targeted Therapy and Immunotherapy?
Upload your medical reports for biomarker-guided treatment evaluation by our oncology team.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.